The Zaltrap Price Debate: Less Than Meets The Eye
This article was originally published in RPM Report
Sanofi is responding to critics of the Zaltrap price with a 50% discount. Is this a “watershed” moment for cancer drug prices? Probably not. The real test will come when payors resist a price on a drug with a proven therapeutic advantage – and when the drug really matters to the sponsor.